These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26276437)

  • 1. Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro.
    Pereira de Sá N; Lino CI; Fonseca NC; Borelli BM; Ramos JP; Souza-Fagundes EM; Rosa CA; Santos DA; Barbosa de Oliveira R; Johann S
    Eur J Med Chem; 2015 Sep; 102():233-42. PubMed ID: 26276437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.
    Sá NP; Lima CM; Lino CI; Barbeira PJS; Baltazar LM; Santos DA; Oliveira RB; Mylonakis E; Fuchs BB; Johann S
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of Natural Acylphloroglucinol-Based Antifungal Compounds against Cryptococcus Species.
    Yu Q; Ravu RR; Jacob MR; Khan SI; Agarwal AK; Yu BY; Li XC
    J Nat Prod; 2016 Sep; 79(9):2195-201. PubMed ID: 27584935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyaldimines as potent in vitro anticryptococcal agents.
    Magalhães TF; da Silva CM; de Fátima Â; da Silva DL; Modolo LV; Martins CV; Alves RB; Ruiz AL; Longato GB; de Carvalho JE; de Resende-Stoianoff MA
    Lett Appl Microbiol; 2013 Aug; 57(2):137-43. PubMed ID: 23594040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal activity of eicosanoic acids isolated from the endophytic fungus Mycosphaerella sp. against Cryptococcus neoformans and C. gattii.
    Pereira CB; Pereira de Sá N; Borelli BM; Rosa CA; Barbeira PJS; Cota BB; Johann S
    Microb Pathog; 2016 Nov; 100():205-212. PubMed ID: 27693577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazole derivatives act on virulence factors of Cryptococcus spp.
    de Sá NP; de Barros PP; Junqueira JC; Vaz JA; de Oliveira RB; Rosa CA; Santos DA; Johann S
    Med Mycol; 2019 Jan; 57(1):84-91. PubMed ID: 29471408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
    Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
    Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal and antibiofilm effect of duloxetine hydrochloride against Cryptococcus neoformans and Cryptococcus gattii.
    Rehem AR; da Gama Viveiro LR; De Souza Santos EL; do Carmo PHF; da Silva NS; Junqueira JC; Scorzoni L
    Folia Microbiol (Praha); 2024 Dec; 69(6):1247-1254. PubMed ID: 38652436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
    Vu K; Gelli A
    Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
    Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
    Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptococcus neoformans/Cryptococcus gattii species complex melanized by epinephrine: Increased yeast survival after amphotericin B exposure.
    Brilhante RSN; Rocha MGD; Oliveira JS; Pereira-Neto WA; Guedes GMM; Cordeiro RA; Sidrim JJC; Rocha MFG; Castelo-Branco DSCM
    Microb Pathog; 2020 Jun; 143():104123. PubMed ID: 32169493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endophytic fungal compounds active against Cryptococcus neoformans and C. gattii.
    Pereira CB; de Oliveira DM; Hughes AF; Kohlhoff M; LA Vieira M; Martins Vaz AB; Ferreira MC; Carvalho CR; Rosa LH; Rosa CA; Alves TM; Zani CL; Johann S; Cota BB
    J Antibiot (Tokyo); 2015 Jul; 68(7):436-44. PubMed ID: 25712396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
    Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
    Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.
    Santos JR; Gouveia LF; Taylor EL; Resende-Stoianoff MA; Pianetti GA; César IC; Santos DA
    Antimicrob Agents Chemother; 2012 May; 56(5):2553-8. PubMed ID: 22290956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].
    Favalessa OC; Ribeiro LC; Tadano T; Fontes CJ; Dias FB; Coelho BP; Hahn RC
    Rev Soc Bras Med Trop; 2009; 42(6):661-5. PubMed ID: 20209351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
    Trilles L; Meyer W; Wanke B; Guarro J; Lazéra M
    Med Mycol; 2012 Apr; 50(3):328-32. PubMed ID: 21859388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.